Aardvark Therapeutics, Inc. (AARD)

NASDAQ: AARD · Real-Time Price · USD

7.74

-1.16 (-13.03%)

At close: Mar 28, 2025, 4:00 PM

7.37

-0.37 (-4.78%)

Pre-market: Mar 31, 2025, 8:49 AM EDT

Aardvark Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Sep '24 Sep 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Selling, General & Admin	4.44	2.17	2.7
Research & Development	10.84	4.48	7.17
Operating Expenses	15.57	7.42	10.36
Operating Income	-15.57	-7.42	-10.36
Interest & Investment Income	1.82	1.42	0.12
EBT Excluding Unusual Items	-13.75	-5.99	-10.24
Gain (Loss) on Sale of Investments	-0.1	-1.22	-2.32
Asset Writedown	-	-	-1
Pretax Income	-13.85	-7.21	-13.56
Net Income	-13.85	-7.21	-13.56
Net Income to Common	-13.85	-7.21	-13.56
Shares Outstanding (Basic)	4	4	4
Shares Outstanding (Diluted)	4	4	4
Shares Change (YoY)	2.06%	1.78%	-
EPS (Basic)	-3.49	-1.82	-3.49
EPS (Diluted)	-3.49	-1.82	-3.49
EBIT	-15.57	-7.42	-10.36

Updated Feb 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q